Menveo consists of two portions: 10 µg of lyophilized meningococcal serogroup A capsular polysaccharide conjugated to CRM197 and 5 μg each of capsular polysaccharide of serogroup C, W, and Y conjugated to CRM197 in 0.5 mL of phosphate-buffered saline, which is used to reconstitute the lyophilized MenA component.
Menveo is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
Menveo is administered as an intramuscular injection.
Menveo is approved for use in persons 2 months through 55 years of age
- In children initiating vaccination at 2 months of age, MENVEO is to be administered as a 4-dose series at 2, 4, 6, and 12 months of age.
- In children initiating vaccination at 7 months through 23 months of age, MENVEO is to be administered as a 2-dose series with the second dose administered in the second year of life and at least 3 months after the first dose.
- In individuals, 2 years through 55 years of age MENVEO is to be administered as a single dose.